Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort StudyRon Ram, Ronen Ben‐Ami, Chen Glait‐Santar et al.|Transplantation and Cellular Therapy|2021Cited by 164
Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort StudyRon Ram, David Hagin, Nili Eilaty et al.|Transplantation and Cellular Therapy|2022Cited by 14